Clinical Trials Browser

Phase 1 × OTHER × Decitabine × Clear all

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07177079 2026-04-09

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03240211 2026-04-07

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Phase 1 Active not recruiting

Lymphoma, T-Cell

NCT03017131 2026-04-06

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07511062 2026-04-06

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07374029 2026-04-03

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06327685 2026-04-01

Avapritinib With Decitabine in Patients With SM-AHN

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03844815 2026-03-04

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07283094 2026-03-03

FHD-286

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT06997094 2026-01-26

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Phase 1 Recruiting

Human Papillomavirus-Negative Neck Squamous Cell Carcinoma

NCT03875287 2026-01-12

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04874480 2026-01-09

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03263936 2025-10-16

Epigenetic Reprogramming in Relapse/Refractory AML

Phase 1 Completed

37 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT07216833 2025-10-15

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Completed

13 enrolled 12 charts

Head and Neck Neoplasms

NCT03009240 2025-06-17

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05222984 2025-05-30

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03063944 2025-05-15

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Phase 1 Terminated

Blast Crisis, Myeloproliferative Disorders

NCT02959164 2023-07-28

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Phase 1 Completed

Sarcoma

NCT03855371 2022-11-04

PANDA-T0

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01834248 2022-07-22

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04655391 2022-06-09

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04252248 2021-10-06

DERANO

Phase 1 Terminated

Head and Neck Neoplasms

NCT02316964 2020-03-09

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT02129101 2019-10-30

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03395873 2019-08-21

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03752138 2019-05-06

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02323607 2019-01-25

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02412475 2019-01-24

Epigenetic Reprogramming in Relapse AML

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00791271 2018-11-09

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Phase 1 Terminated

Melanoma

NCT02264873 2018-10-15

Phase I, Dose Escalation Study of Decitabine

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01876641 2018-09-19

ML28604

Phase 1 Terminated

Melanoma

NCT01352650 2018-07-02

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01798901 2018-03-14

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT02141477 2018-02-13

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02093403 2017-12-08

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01241162 2017-05-09

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Phase 1 Completed

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT02564536 2017-05-08

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02234037 2017-01-30

Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

Phase 1 Terminated

Other hematologic neoplasm

Leukemia